AGENDA: Do not miss!!
We will celebrate the World TB Day
at Palau Macaya, Barcelona (thanks to the LaCaixa Foundation), on 22th March 2017, from 10 am to 3 pm.
Organized by the FUITB.
Tag Archives: Clinical Trial
We spent last tweek in Tbilisi, Georgia, to prepare the start of our 2 new CT to evaluate hostdirected therapies: ibuprofen and the nutraceutical Nyaditum resae. A pilot CT will evaluate ibuprofen as coadjuvant treatment for Pre-XDR and XDR-TB; and … Continue reading
We are happy to announce that we are going to conduct a pilot clinical trial in the NCTLD in Tbilisi, Georgia to evaluate the potential benefit and safety of ibuprofen as coadjuvant in the treatment of XDR-TB cases. The study … Continue reading
“Towards host-directed therapies for tuberculosis”: a position comment published in Nature Reviews Drug Discovery by the HDT network.
The prestigious journal Nature Reviews Drug Discovery has published the The Host-Directed Therapies Network (HDT-NET) views and consensus as a comment article. The HDT-NET was founded last spring (April, 7th 2015) by Pr. Alimuddin Zumla and Pr. Markus Maeurer, and gathers 29 African … Continue reading
The Experimental Tuberculosis Unit, together with the Pharmacology Dept of the Hospital Universitari Germans Trias i Pujol and the Clinical Trials’ Unit of the IGTP, present today the results of NYADATREG (ClinicalTrials.gov Identifier: NCT02076139) , the first clinical trial conducted … Continue reading
Dr Cardona and the other members of the team involved in the Phase II CT of the therapeutic vaccine RUTI® have published the results of the study registered in ClinicalTrials.gov as NCT01136161. Conducted in SouthAfrica, the aim of the study was to evaluate … Continue reading
Dear all, yesterday was a sad day for TB vaccines. The Lancet published the final results of the study in which lots of us hoped for: to prove the efficacy of a new TB vaccine, the highly promising MVA85A, the first one … Continue reading
Because besides a good product, money is needed. The media published yesterday the entry of a new group (TGT) in Archivel Farma (the biotech developing RUTI). TGT has bought the 41,8% of the company owned by Fons Innocat (managed by … Continue reading